Low-Concentration Ergoline Autoinjector for Rapid Headache Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for migraines and cluster headaches, such as triptans and dihydroergotamine (DHE), require clinical administration, leading to delayed treatment, variable absorption, and side effects, making them inconvenient and ineffective for many patients.

Innovation Solution

A preassembled, prefilled, single-use delivery device containing a low concentration of ergoline derivatives like dihydroergotamine, allowing self-administration outside a clinical setting through an autoinjector for rapid and consistent treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high concentration of ergoline derivative is administered, then treatment effectiveness is improved, but side effects increase

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the concentration parameter of the ergoline derivative from high to low (1.5 mg/mL or less), and compensates by optimizing the delivery mechanism (autoinjector for rapid subcutaneous absorption) to maintain treatment effectiveness while reducing side effects

Inventive Principle:

Principle #35Parameter changes

2Reliability

If clinical administration is required, then treatment safety is improved, but treatment time is delayed

Engineering Contradiction:

Improvetreatment safetyVSAvoidtreatment time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent enables patients to self-administer the medication using a pre-assembled, prefilled, single-use autoinjector device, eliminating the need for clinical administration while maintaining safety through standardized dosing and proper device design

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The medication is pre-filled into the autoinjector device in advance, so that when a migraine attack occurs, the patient can immediately administer the treatment without waiting for clinical preparation, significantly reducing treatment time

Inventive Principle:

Principle #10Preliminary action

3Ease of operation

If oral dosage form is used, then ease of administration is improved, but absorption consistency deteriorates

Engineering Contradiction:

Improveease of administrationVSAvoidabsorption consistency

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent replaces the gastrointestinal absorption pathway (oral route) with a parenteral delivery system (subcutaneous autoinjector), which provides more consistent and predictable absorption kinetics while still maintaining ease of patient administration

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS20250381170A1Low Concentration Delivery of an Ergoline Derivative for Treatment of a Headache

Publication Date: 2025.12.18 RELEVALE INC

AI summary

Provided are ergoline derivative containing medicaments disposed within a preassembled, prefilled, single-use delivery device, methods for administering a medicament using a preassembled, prefilled, single-use delivery device, and systems or kits that contain one or more preassembled, prefilled, single-use devices and user instructions, such as for treatment of a migraine or other headache.